After Leerink Partners and Wedbush gave Blueprint Medicines (NASDAQ: BPMC) a Buy rating last month, the company received another Buy, this time from JMP Securities. Analyst Reni Benjamin maintained a Buy rating on Blueprint Medicines yesterday and set a price target of $152.00. The company’s shares closed last Monday at $80.56.
According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.1% and a 31.2% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $117.11 average price target, a 49.4% upside from current levels. In a report issued on January 24, Stifel Nicolaus also upgraded the stock to Buy with a $95.00 price target.
Based on Blueprint Medicines’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $24.19 million and GAAP net loss of $117 million. In comparison, last year the company earned revenue of $745 million and had a net profit of $634 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Read More on BPMC: